BAM15 vs Retatrutide
A side-by-side research comparison of BAM15 and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | Retatrutide |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 402.28 Da | 5,200 Da (approximate) |
| Half-life | Short (hours in animal models) | 6 days |
| Bioavailability | Oral (animal studies) | High (SubQ) |
| Typical dose | Not established for humans | 1-2 mg → titrate up to 12 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Oral (research) | Subcutaneous injection |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.